In Silico Identification of Potential Inhibitors of the Main Protease of SARS-CoV-2 Using Combined Ligand-Based and Structure-Based Drug Design Approach
Objectives: The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a serious global threat. At the time of writing, there are no specific therapeutic agents or vaccines to combat this disease. This study was designed to identify the SARS-CoV-2 main protease inhibitors using drug molecule information retrieved from DrugBank 5.0 (Wishart et al.)
Methods: A set of common pharmacophores were generated from a series of 22 known SARS-CoV inhibitors. The best pharmacophore used for virtual screening (VS) of DrugBank using the Phase module followed by structure-based virtual screening (VS) using Glide (Release 2020-1; Schrödinger LLC, New York, NY, USA) with SARS-CoV-2 main protease and 50 ns molecular dynamics (MD) simulation studies.
Results: Six hits were selected based on the fitness score, extra-precision Glide score, and binding affinity with the main protease (Mpro). The predicted inhibitor constant (Ki) values of the 3 best hits, DB03777, DB06834, and DB07456, were 0.8176, 0.2148, and 0.1006 μM, respectively. An MD simulation of DB07456 and DB13592 with the Mpro demonstrated stable protein-ligand complexes.
Conclusion: The selected inhibitors displayed a similar type of binding interaction with co-ligands and remdesivir, and the predicted Ki values of 2 inhibitors were found to be superior to remdesivir. These selected hits may be used for further in vitro and in vivo studies against the SARS-CoV-2 Mpro.
1.Smith RD. Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management. Soc Sci Med 2006;63:3113–23.
2. WHO. Middle East Respiratory Syndrome Coronavirus (MERSCoV) – United Arab Emirates. Available at: https://www.who. int/csr/don/31-january-2020-mers-united-arab-emirates/en/. Accessed Jan 31, 2020.
3. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B 2020;10:766–88.
4. Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today 2020;25:668–88.
5. Pillaiyar T, ManickamM, Namasivayam V, Hayashi Y, Jung SH. An Overview of Severe Acute Respiratory Syndrome– Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J Med Chem 2016;59:6595–628.
6. Snijder EJ, Decroly E, Ziebuhr J. The Non-structural Proteins Directing Coronavirus RNA Synthesis and Processing. Adv Virus Res 2016;96:59–126.
7. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020;10:102–8.
8. Dagur HS, Dhakar SS. Genome Organization of Covid-19 and Emerging Severe Acute Respiratory Syndrome Covid-19 Outbreak: A Pandemic. EJMO 2020;4:107–15.
9. Liu X, Wang XJ. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv. 2020 Jan 29. doi: https://doi.org/10.1101/2020.01.29.924100. [Epub ahead of print].
10. Li G, Clercq ED. Therapeutic options for the 2019 novel coro-navirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149–50.
11. Contini A. Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins. ChemRxiv. 2020 Feb 13. doi: https://doi.org/10.26434/chemrxiv.11847381.v1. [Epub ahead of print].
12. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Networkbased drug repurposing for novel coronavirus 2019-nCoV/ SARS-CoV-2. Cell Discov 2020;6:14.
13. Li Y, Zhang J, Wang N, Li H, Shi Y, Guo G, et al. Therapeutic Drugs Targeting 2019-nCoV Main Protease by HighThroughput Screening. bioRxiv. 2020 Jan 30. doi: https://doi. org/10.1101/2020.01.28.922922. [Epub ahead of print].
14. Narkhede RR, Cheke RS, Ambhore JP, Shinde SD. The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2. EJMO 2020;4:185–95.
15. Tan YJ, Lim SG, Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Research Antivir Res 2005;65:69–78.
16. Grahama RL, Sparks JS, Eckerle LD, Sims AC, Denison MR. SARS coronavirus replicase proteins in pathogenesis.Virus Res 2008;133:88–100.
17. Chen L, Gui C, Luo X, Yang Q, Günther S, Scandella E, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 2005;97:7095–103.
18. Jo S, Kim S, Shin DH. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzym Inhib Med Chem 2020;35:145–51.
19. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential Inhibitor of COVID-19 Main Protease (Mpro) from Several Medicinal Plant Compounds by Molecular Docking Study. Preprints. 2020 Mar 12. doi: 10.20944/preprints202003.0226.v1. [Epub ahead of prints].
20. Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: An in Silico Strategy Unveils a Hope against CORONA. Preprints. 2020 Mar 21. doi: 10.20944/preprints202003.0333.v1. [Epub ahead of prints].
21. Liu X, Zhang B, Jin Z, Yang H, Rao Z. The crystal structure of COVID-19 main protease in complex with an inhibitor N3. Available at: https://www.wwpdb.org/pdb?id=pdb_00006lu7. Accessed Feb 5, 2020.
22. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46:D1074–D82.
23. Schrödinger, LLC, LigPrep, 2020. Available at: https://www. schrodinger.com/ligprep. Accessed Dec 4, 2020.
24. Schrödinger, LLC, Protein Preparation Wizard; Epik, 2020. Available at: https://www.schrodinger.com/protein-preparation-wizard. Accessed Dec 4, 2020.
25. Schrödinger, LLC, Prime, 2020. Available at: https://www.schrodinger.com/prime. Accessed Dec 4, 2020.
26. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, et al. A hierarchical approach to all-atom protein loop prediction. Proteins 2004;55:351–67.
27. Jacobson MP, Friesner RA, Xiang Z, Honig B. On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 2002;320:597–608.
28. Schrödinger, LLC, Phase, 2020. Available at: https://www.schrodinger.com/phase. Accessed Dec 4, 2020.
29. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 2006;20:647–71.
30. Dixon SL, Smondyrev AM, Rao SN. PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 2006;67:370–2.
31. Schrödinger, LLC, Glide, 2020. Available at: https://www.schrodinger.com/glide. Accessed Dec 4, 2020.
32. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
33. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for proteinligand complexes. J Med Chem 2006;49:6177–96.
34. Schrödinger, LLC, QikProp, 2020. Available at: https://www. schrodinger.com/qikprop. Accessed Dec 4, 2020.
35. D. E. Shaw Research. Desmond Molecular Dynamics System. Available at: https://www.deshawresearch.com/resources_ desmond.html. Accessed Dec 4, 2020.
36. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein M.L. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926–35.
37. Yoshino R, Yasuo N, Sekijima M. Identification of key interactions between SARS-CoV-2 mainprotease and inhibitor drug candidates. Scientific Reports 2020;10:12493.
38. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell D, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem 2009;30:2785–91.
39. Mukherjee P, Shah F, Desai P, Avery M. Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies. J Chem Inf Model 2011;51:1376–92.
40. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA 2003;100:13190–5.
41. Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int JMol Sci 2020;21:2657.
42. Kufareva I, Abagyan R. Methods of protein structure comparison. Methods in Molecular Biology 2012;857:231–57.
43. Wang J. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. J Chem Inf Model 2020;60:3277−86.